290 related articles for article (PubMed ID: 27326858)
1. OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
Böhm R; von Hehn L; Herdegen T; Klein HJ; Bruhn O; Petri H; Höcker J
PLoS One; 2016; 11(6):e0157753. PubMed ID: 27326858
[TBL] [Abstract][Full Text] [Related]
2. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
[TBL] [Abstract][Full Text] [Related]
3. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
4. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
Huang J; Jia Y; Sun S; Meng L
BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
[TBL] [Abstract][Full Text] [Related]
5. OpenVigil--free eyeballs on AERS pharmacovigilance data.
Böhm R; Höcker J; Cascorbi I; Herdegen T
Nat Biotechnol; 2012 Feb; 30(2):137-8. PubMed ID: 22318027
[No Abstract] [Full Text] [Related]
6. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
[TBL] [Abstract][Full Text] [Related]
7. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.
Wang K; Wan M; Wang RS; Weng Z
J Med Internet Res; 2016 Apr; 18(4):e76. PubMed ID: 27036325
[TBL] [Abstract][Full Text] [Related]
8. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.
Raschi E; Piccinni C; Poluzzi E; Marchesini G; De Ponti F
Acta Diabetol; 2013 Aug; 50(4):569-77. PubMed ID: 22008948
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
[TBL] [Abstract][Full Text] [Related]
10. Harnessing scientific literature reports for pharmacovigilance. Prototype software analytical tool development and usability testing.
Sorbello A; Ripple A; Tonning J; Munoz M; Hasan R; Ly T; Francis H; Bodenreider O
Appl Clin Inform; 2017 Mar; 8(1):291-305. PubMed ID: 28326432
[TBL] [Abstract][Full Text] [Related]
11. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
Kadoyama K; Sakaeda T; Tamon A; Okuno Y
Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
13. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
Sakaeda T; Kadoyama K; Okuno Y
PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
[TBL] [Abstract][Full Text] [Related]
14. Leveraging MEDLINE indexing for pharmacovigilance - Inherent limitations and mitigation strategies.
Winnenburg R; Sorbello A; Ripple A; Harpaz R; Tonning J; Szarfman A; Francis H; Bodenreider O
J Biomed Inform; 2015 Oct; 57():425-35. PubMed ID: 26342964
[TBL] [Abstract][Full Text] [Related]
15. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
17. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data.
Kass-Hout TA; Xu Z; Mohebbi M; Nelsen H; Baker A; Levine J; Johanson E; Bright RA
J Am Med Inform Assoc; 2016 May; 23(3):596-600. PubMed ID: 26644398
[TBL] [Abstract][Full Text] [Related]
18. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
[TBL] [Abstract][Full Text] [Related]
19. The Internet and drug safety: what are the implications for pharmacovigilance?
Cobert B; Silvey J
Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
[TBL] [Abstract][Full Text] [Related]
20. Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants.
Ehrenpreis ED; Sifuentes H; Ehrenpreis JE; Smith ZL; Marshall ML
Expert Opin Drug Saf; 2012 Mar; 11(2):177-83. PubMed ID: 22316142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
